

WHAT OUTCOMES MATTER MOST IN STUDIES OF PULMONARY TB TREATMENTS?

VERSION 2

REGISTER FOR
THE STUDY HERE



[HTTPS://DELPHIMANAGER.LIVERPOOL.AC.UK/UNITE4COS/DELPHI](https://delphimanager.liverpool.ac.uk/unite4cos/delphi)

FOR MORE INFORMATION PLEASE
EMAIL:

UNITE4COS@LIVERPOOL.AC.UK

WE INVITE YOU TO TAKE PART IN AN ONLINE RESEARCH SURVEY

If you have experience of being treated for tuberculosis of the lung or you have cared for someone who has.

If you are a researcher developing pulmonary TB treatments.

If you are a healthcare worker treating people diagnosed with pulmonary tuberculosis

WHY ARE WE DOING THIS STUDY?

TB is caused by bacteria (*Mycobacterium tuberculosis*) and often affects the lungs. Each year approximately 10 million people fall ill with the disease. The bacteria is also becoming increasingly resistant to the treatments. Improving current treatments and finding new treatments is therefore very important.

Unfortunately, different research studies of treatments for pulmonary tuberculosis (TB in the lungs), often measure different outcomes. This makes it difficult to find out which treatments might be best for patients as the results of different studies cannot be compared or combined

The UNITE4COS study needs your help to find out what outcomes are so important that they should always be measured in studies for pulmonary TB. We call these the core outcomes. If all future studies for pulmonary TB measure these core outcomes and measure them in similar ways, the results of the studies can be easily compared and combined. This may help new, effective treatments become available to patients more quickly.